151 related articles for article (PubMed ID: 18586385)
1. Applications of novel monoclonal antibodies specific for synuclein-gamma in evaluating its levels in sera and cancer tissues from colorectal cancer patients.
Liu C; Guo J; Qu L; Bing D; Meng L; Wu J; Shou C
Cancer Lett; 2008 Sep; 269(1):148-58. PubMed ID: 18586385
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis.
Hu H; Sun L; Guo C; Liu Q; Zhou Z; Peng L; Pan J; Yu L; Lou J; Yang Z; Zhao P; Ran Y
Clin Cancer Res; 2009 Sep; 15(17):5485-93. PubMed ID: 19706805
[TBL] [Abstract][Full Text] [Related]
3. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers.
Liu H; Liu W; Wu Y; Zhou Y; Xue R; Luo C; Wang L; Zhao W; Jiang JD; Liu J
Cancer Res; 2005 Sep; 65(17):7635-43. PubMed ID: 16140929
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression and demethylation of gamma-synuclein in colorectal cancer, correlated with progression of the disease.
Ye Q; Zheng MH; Cai Q; Feng B; Chen XH; Yu BQ; Gao YB; Ji J; Lu AG; Li JW; Wang ML; Liu BY
Cancer Sci; 2008 Oct; 99(10):1924-32. PubMed ID: 19016751
[TBL] [Abstract][Full Text] [Related]
5. Expression of alpha-, beta- and gamma-synuclein in colorectal cancer, and potential clinical significance in progression of the disease.
Ye Q; Wang TF; Peng YF; Xie J; Feng B; Qiu MY; Li LH; Lu AG; Liu BY; Zheng MH
Oncol Rep; 2010 Feb; 23(2):429-36. PubMed ID: 20043104
[TBL] [Abstract][Full Text] [Related]
6. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration.
Zhao W; Liu H; Liu W; Wu Y; Chen W; Jiang B; Zhou Y; Xue R; Luo C; Wang L; Jiang JD; Liu J
Int J Oncol; 2006 May; 28(5):1081-8. PubMed ID: 16596223
[TBL] [Abstract][Full Text] [Related]
7. Stage-specific expression of breast cancer-specific gene gamma-synuclein.
Wu K; Weng Z; Tao Q; Lin G; Wu X; Qian H; Zhang Y; Ding X; Jiang Y; Shi YE
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):920-5. PubMed ID: 14504205
[TBL] [Abstract][Full Text] [Related]
8. Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.
Guo J; Shou C; Meng L; Jiang B; Dong B; Yao L; Xie Y; Zhang J; Chen Y; Budman DR; Shi YE
Int J Cancer; 2007 Sep; 121(6):1296-305. PubMed ID: 17534899
[TBL] [Abstract][Full Text] [Related]
9. Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells.
Inaba S; Li C; Shi YE; Song DQ; Jiang JD; Liu J
Breast Cancer Res Treat; 2005 Nov; 94(1):25-35. PubMed ID: 16142440
[TBL] [Abstract][Full Text] [Related]
10. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
[TBL] [Abstract][Full Text] [Related]
11. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer.
Czekierdowski A; Czekierdowska S; Wielgos M; Smolen A; Kaminski P; Kotarski J
Neuro Endocrinol Lett; 2006 Jun; 27(3):381-6. PubMed ID: 16816827
[TBL] [Abstract][Full Text] [Related]
12. Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs.
Singh VK; Zhou Y; Marsh JA; Uversky VN; Forman-Kay JD; Liu J; Jia Z
Cancer Res; 2007 Jan; 67(2):626-33. PubMed ID: 17234772
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
Zhou Y; Inaba S; Liu J
Int J Oncol; 2006 Jul; 29(1):289-95. PubMed ID: 16773211
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of synuclein-γ levels by novel monoclonal antibody in saliva and cancer tissues from oral squamous cell carcinoma patients.
Wang K; Shen Y; Xu J; Li Z; Liu Y; Yu C; Peng L; Zheng J; Zeng Y
Neoplasma; 2020 May; 67(3):707-713. PubMed ID: 32202903
[TBL] [Abstract][Full Text] [Related]
15. [Identification of antigenic epitope regions recognized by anti-synuclein-gamma monoclonal antibodies].
Xie W; Su YH; Liu CY; Shou CC
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Jun; 41(3):361-7. PubMed ID: 19727223
[TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of monoclonal antibodies against phosphatidylethanolamine binding protein 1 in pancreatic cancer patients.
Wang X; Wang S; Tang X; Zhang A; Grabinski T; Guo Z; Hudson E; Berghuis B; Webb C; Zhao P; Cao B
J Immunol Methods; 2010 Oct; 362(1-2):151-60. PubMed ID: 20869966
[TBL] [Abstract][Full Text] [Related]
17. Identification of S100A8 and S100A9 as serological markers for colorectal cancer.
Kim HJ; Kang HJ; Lee H; Lee ST; Yu MH; Kim H; Lee C
J Proteome Res; 2009 Mar; 8(3):1368-79. PubMed ID: 19186948
[TBL] [Abstract][Full Text] [Related]
18. [Influence of SNCG transfection on the effectiveness of anti-tumor drugs in PC-3 cell lines].
Chen JL; Wang B; Zhang LR; He BS; Pan YQ; Zeng QD; Jiang HX; Wang SK
Zhonghua Nan Ke Xue; 2008 Dec; 14(12):1077-82. PubMed ID: 19157226
[TBL] [Abstract][Full Text] [Related]
19. Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases.
Li J; Guo K; Koh VW; Tang JP; Gan BQ; Shi H; Li HX; Zeng Q
Clin Cancer Res; 2005 Mar; 11(6):2195-204. PubMed ID: 15788667
[TBL] [Abstract][Full Text] [Related]
20. Identification of endothelial cell-specific molecule-1 as a potential serum marker for colorectal cancer.
Ji NY; Kim YH; Jang YJ; Kang YH; Lee CI; Kim JW; Yeom YI; Chun HK; Choi YH; Kim JH; Kim JW; Lee HG; Song EY
Cancer Sci; 2010 Oct; 101(10):2248-53. PubMed ID: 20735430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
